Senti Biosciences Holdings (SNTI) Current Assets (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Current Assets of $23.3 million for Q4 2025, down 60.53% year-over-year from $59.0 million in Q4 2024, and up 28.17% quarter-over-quarter from $18.2 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Current Assets (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Current Assets history runs 5 years deep, the most recent figure standing at $23.3 million for Q4 2025.
- In Q4 2025, Current Assets fell 60.53% year-over-year to $23.3 million; the TTM figure through Dec 2025 stood at $23.3 million (down 60.53% YoY), while the FY2025 annual figure was $23.3 million, down 60.53% from the prior year.
- Current Assets for Q4 2025 stood at $23.3 million, up from $18.2 million in the prior quarter.
- The five-year high for Current Assets was $143.9 million in Q2 2022, with the low at $827152.0 in Q1 2022.
- The 5-year median for Current Assets is $55.7 million (2024), against an average of $53.7 million.
- The sharpest annual moves came in 2023 and 2024: Current Assets soared 9633.52% in 2023, then tumbled 78.0% in 2024.
- Senti Biosciences Holdings' Current Assets stood at $60.2 million in 2021, then soared by 70.42% to $102.6 million in 2022, then plunged by 30.59% to $71.2 million in 2023, then retreated by 17.19% to $59.0 million in 2024, then sank by 60.53% to $23.3 million in 2025.
- Business Quant data shows SNTI's Current Assets at $23.3 million in Q4 2025, $18.2 million in Q3 2025, and $32.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 1.76 Bn |
| 10 | Senti Biosciences Holdings | 12.74 Mn | 12.74 Mn | - | 13.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 23.27 Mn |
| Sep 30, 2025 | 18.16 Mn |
| Jun 30, 2025 | 32.52 Mn |
| Mar 31, 2025 | 45.21 Mn |
| Dec 31, 2024 | 58.96 Mn |
| Sep 30, 2024 | 17.38 Mn |
| Jun 30, 2024 | 44.34 Mn |
| Mar 31, 2024 | 55.67 Mn |
| Dec 31, 2023 | 71.20 Mn |
| Sep 30, 2023 | 79.01 Mn |
| Jun 30, 2023 | 63.49 Mn |
| Mar 31, 2023 | 80.51 Mn |
| Dec 31, 2022 | 102.58 Mn |
| Sep 30, 2022 | 119.76 Mn |
| Jun 30, 2022 | 143.92 Mn |
| Mar 31, 2022 | 827,152.00 |
| Dec 31, 2021 | 60.19 Mn |
| Sep 30, 2021 | 1.66 Mn |
| Jun 30, 2021 | 1.88 Mn |